Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
HL

WKN: A3DMBV | ISIN: DK0061804770 | Ticker: LDBA
Stuttgart
18.11.26 | 17:32
8,280 Euro
+2,22 % +0,180
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
H LUNDBECK A/S B Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S B 5-Tage-Chart
RealtimeGeldBriefZeit
8,2558,31517:56
8,2658,30517:56

Aktuelle News zur H LUNDBECK Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiLundbeck auf der Jefferies Global Healthcare Conference: Wachstumsbasis verbreitert sich2
11.11.Earnings Call: Lundbeck hebt Jahresausblick 2026 nach starkem Neunmonatswachstum an6
10.11.Lundbeck Raises FY26 Revenue, EBITDA Growth Outlook; Shares Up5
10.11.H. Lundbeck A/S Profit Advances In Q31
10.11.H. Lundbeck A/S: Lundbeck raises full-year guidance as 9M revenue grows +13% CER (+11% CER underlying) and adjusted EBITDA +19% CER, led by Vyepti589Lundbeck raises full-year guidance as 9M revenue grows +13% CER (+11% CER underlying) and adjusted EBITDA +19% CER, led by Vyepti VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- Key highlightsLundbeck's...
► Artikel lesen
H LUNDBECK Aktie jetzt für 0€ handeln
10.11.H. Lundbeck A/S: Lundbeck raises financial guidance for 2026408Lundbeck raises financial guidance for 2026 VALBY, Denmark, Nov. 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) raises its full-year 2026 guidance for revenue and adjusted EBITDA growth at...
► Artikel lesen
08.11.405.262 US-Dollar pro Demenzfall - 70% tragen Familien: Warum Axsome, Lundbeck und NeuroThera beim Kostentreiber Agitation ansetzen
18.10.Changes to the Board of Directors of H. Lundbeck A/S703Changes to the Board of Directors of H. Lundbeck A/S Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. Following...
► Artikel lesen
06.10.H. Lundbeck A/S: Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins416Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The...
► Artikel lesen
02.10.H. LUNDBECK A/S: Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS 20263
01.10.H. Lundbeck A/S: Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy348Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following...
► Artikel lesen
29.09.Bloomberg: Lundbeck prüft Übernahme von Xeris Biopharma26
29.09.Xeris Biopharma jumps on report of interest from H Lundbeck7
28.09.H. Lundbeck A/S: Lars Bang, Executive Vice President, Product Development & Supply, has passed away510Valby, Denmark, 28 September, 2026 - H. Lundbeck A/S (Lundbeck) It is with profound sadness that we share that Lars Bang, Executive Vice President, Product Development & Supply, has passed away. Lars...
► Artikel lesen
25.09.Lundbeck to move US digs to Boston as it eyes bigger innovation frontiers-
25.09.H. Lundbeck A/S: Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters831The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships.The move is part of Lundbeck's...
► Artikel lesen
21.09.H. LUNDBECK A/S: Correction - Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties1
21.09.H Lundbeck stock upgraded by UBS on bexicaserin trial potential7
17.09.H. LUNDBECK A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties1
16.09.H. Lundbeck A/S: Lundbeck receives marketing authorization for Vyepti (eptinezumab) in Japan for the prevention of migraine attacks627Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW)Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks...
► Artikel lesen
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1